There is substantial clinical evidence that Δ9-tetrahydrocannabinol (Δ9-THC) and its
synthetic analogs (nabilone and levonantradol) can prevent emesis in cancer patients …

Activation of cannabinoid CB1 receptors inhibits gastrointestinal motility, propulsion, and
transit, whereas selective antagonism of these receptors has the opposite effects …

We have studied the effect of WIN 55,212-2 (a psychoactive cannabinoid agonist),
cannabinol (a non-psychoactive cannabinoid agonist), SR141716A, a cannabinoid CB 1 …

Cannabis has been used for centuries in the medicinal treatment of gastrointestinal
disorders. Endogenous cannabinimimetic substances such as 2-arachidonylglycerol have …

The endocannabinoid system (ECS) is an endogenous signalling pathway involved in the
control of several gastrointestinal (GI) functions at both peripheral and central levels. In …

In the digestive tract there is evidence for the presence of high levels of endocannabinoids
(anandamide and 2-arachidonoylglycerol) and enzymes involved in the synthesis and …

We have studied the effects of the cannabinoid receptor agonists (R)-(+)[2, 3-dihydro-5-
methyl-3-(4-morpholinylmethyl) pyrrolo [1, 2, 3-de]-1, 4-benzoxazin-6-yl]-1 …

We have recently shown that the cannabinoid CB1 receptor antagonist, SR 141716A,
produces emesis in the least shrew (Cryptotis parva) in a dose-and route-dependent …

Based on binding, functional, and pharmacological data, this study introduces SR147778 [5-
(4-bromophenyl)-1-(2, 4-dichloro-phenyl)-4-ethyl-N-(1-piperidinyl)-1 H-pyrazole-3 …

Large doses (10–40 mg/kg) of the selective cannabinoid CB1 receptor antagonist, SR
141716A, produce the head-twitch response (HTR) and scratching in rodents and vomiting …